Legacy Edge Advisors’s DexCom DXCM Stock Holding History

Legacy Edge Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,600	Closed	-$222K	–	176
2024 Q1	$222K	Buy	+1,600	New	+$201K	0.05%	157

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Legacy Edge Advisors's DXCM Position: Q2 2024 in Review

Legacy Edge Advisors sold out of DexCom (DXCM) in Q2 2024, closing a stake of 1,600 shares — an estimated $222K sold.

Legacy Edge Advisors first reported a position in DXCM in Q1 2024 and held it in 1 quarter. The position peaked at $222K in Q1 2024. 1,000 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

Legacy Edge Advisors reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
Legacy Edge Advisors sold 1,600 DexCom shares in Q2 2024, an estimated $222K.
Legacy Edge Advisors first reported a position in DexCom in Q1 2024 and held it in 1 quarter.
Legacy Edge Advisors's DexCom position peaked at $222K in Q1 2024.
1,000 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on Legacy Edge Advisors's 13F filing for Q2 2024, filed 17 Aug 2026.